are mainly in tissue-specific gene regulation and determination of cell fate, whereas cytoplasmic LIM domain proteins are mainly involved in cytoskeleton organization. 10, 11 Multiple functions have been ascribed to FHL2. FHL2 acts as a transcriptional cofactor through interaction with a broad range of transcription factors, and it forms diverse protein complexes in many cell types. It, therefore, modulates the activity and expression of several proteins, including, but not limited to, androgen receptor, cyclic adenosine monophosphate response element-binding protein, integrins, β-catenin, presenilin-2, extracellular signal-regulated kinase-2, activator protein-1, and sphingosine kinase-1 (SK-1). [12] [13] [14] [15] [16] [17] In so doing, FHL2 modulates cellular processes such as signal transduction, cell proliferation, and survival. 18 FHL2 is strongly expressed in early cardiac precursor cells, in the adult heart, in skeletal muscle, and to a lower extent in most epithelial tissues. 19, 20 Recently, FHL2 expression has been demonstrated in ECs and vascular smooth muscle cells of the vessel wall. 21, 22 Overexpression of FHL2 inhibits vascular endothelial growth factor-induced EC migration via suppression of the SK-1/sphingosine-1-phosphate (S1P) pathway. 23 FHL2 interacts with and inhibits the activity of SK-1, which is the enzyme responsible for S1P production. [24] [25] [26] Deletion of FHL2 in mice is associated with reduced atherogenesis 22 and changes in vascular smooth muscle phenotype and endothelial function. 27 However, the role of FHL2 in EOCs is presently unknown. In this study, we investigated the role of FHL2 in the regulation of EOC number and function in vitro and their reendothelialization capacity in vivo.
Methods
An expanded Methods section describing all procedures and protocols is available in the Online Data Supplement.
Preparation of EOCs
Mononuclear cells were isolated from peripheral blood of healthy donors (age 20-45 years; men and women; no known disease or medication) using a Ficoll density gradient (Sigma) according to standard protocols as previously described. 28 Blood cell donation was approved by the research review committee of the Lady Davis Institute for Medical Research.
For mouse mononuclear cells, male 8-to 10-week-old, wildtype (WT) and FHL2 knockout (FHL2 −/− ) mice with C57BL/6J background, initially provided by Dr Büttner, University of Bonn, Germany, were used. Spleens were explanted, mechanically minced, and mononuclear cells isolated using a Ficoll gradient, as previously described. 28, 29 We have previously characterized cultured human EOCs by immunocytochemistry. 28 
Transfection With siRNA
Human EOCs were transfected at day 6 of cell culture with a specific FHL2 siRNA (siFHL2; 5 nmol/L; Qiagen) or luciferase siRNA (siLuci), used as transfection control siRNA (Qiagen), for 24 hours in endothelial basal medium with supplements (Cedarlane) by using HiPerFect transfection reagent (Qiagen).
Apoptosis
Cleaved (active) caspase-III immunocytochemistry was performed as previously described. 28 Fluorescence was visualized with a DM2000 microscope (Leica Microsystems). As an additional approach, the Bax/Bcl-2 expression ratio was assessed by Western blot, as previously described.
28

Migration
Migratory capacity was evaluated by using modified Boyden chambers (8 µm pore size; Becton Dickinson), as previously described. 28 EC migratory capacity was evaluated by using the scratch assay.
Carotid Endothelial Injury
All procedures were approved by the Animal Care Committees of McGill University and have followed recommendations of the Canadian Council on Animal Care.
Statistical Analysis
Results are expressed as means±SEM. All data were evaluated by ANOVA. Statistical significance for comparisons between 2 groups was calculated using the 2-tailed Student t test. To assess comparisons between multiple groups, data were analyzed using the Newman-Keuls test. A probability value <0.05 was considered statistically significant. Data that were significant (P<0.05) were further assessed by Student t test using GraphPad Prism software (GraphPad Software).
Results
FHL2 Knockdown Increases EOC Numbers Through Decreased Apoptosis
FHL2 is expressed in the cytosol as well as in the nucleus of human EOCs, as assessed by immunocytochemistry ( Figure 1A ). To determine the role of FHL2 in EOCs in vitro, we used specific siRNA against FHL2 that inhibited FHL2 protein expression levels by 40% compared with luciferase siRNA (used as control siRNA; Figure 1B ). The transfection efficiency, determined by FITC-coupled control RNA, was 57.5% (data not shown). FHL2 knockdown significantly increased the number of cultured human EOCs, as determined by immunostaining of fibronectin-adherent cells with Dil-acetylated low density lipoprotein (acLDL) and lectin ( Figure 1C ). Because the rate of proliferating cells, as determined by Ki67 immunocytochemistry, was low (<1%) in EOCs (Figure 2A) , and because the FHL2 siRNA did not influence adhesion of EOCs to the substrate (Online Figure I) , we assessed apoptosis. We found that there was a significant decrease of apoptotic EOCs, as determined by cleaved (active) caspase-III expression in Dil-acLDL/lectin double-positive cells ( Figure 2B ), by Bax/Bcl-2 expression ratio ( Figure 2C ), and by Annexin V staining (Online Figure  IIB) , all of which are molecular indices of apoptosis. analysis ( Figure 3B ). In contrast, no difference was observed in the number of cells expressing the active forms of β1 or β2 integrins ( Figure 3B ). There were no differences in the mean fluorescence intensities of the integrin signals (Online Figure  IV) , indicating that surface expression of integrins was an all-or-none phenomenon in EOCs. To evaluate if increased EOC migration by FHL2 inhibition was mediated through this upregulation of αv/β3 and αv/β5 or through β1 or β2, which are known to participate in cell migration, we used integrin-neutralizing antibodies. Neither anti-β1 antibody nor IgG control prevented the enhanced migration in siFHL EOCs compared with siLuci EOCs ( Figure 3C ). However, the difference between siFHL-and siLuci-transfected EOCs was abolished in the presence of αv/β3, αv/β5, or β2-neutralizing antibodies. Furthermore, we found a significant increase in cortactin expression in EOCs transfected with siFHL2 versus siLuci, as determined by immunocytochemistry ( Figure 3D ).
Cortactin is an F-actin-binding protein that plays an important role in actin filament assembly and cell motility. These results suggest that knockdown of FHL2 increases SDF-1-induced migration through upregulation of αv/β3, αv/β5, and β2 integrins as well as cortactin.
FHL2 Knockdown Decreases Apoptosis and Increases Migration of EOCs Through Activation of the SK-1/S1P Pathway
To determine the molecular pathway involved in the effects of FHL2 knockdown on human EOC apoptosis and migration, we investigated the SK-1 pathway. FHL2 was shown to bind to and suppress the activity of SK-1, the enzyme producing S1P, in cardiomyocytes. [24] [25] [26] We observed a significant increase in SK-1 phosphorylation ( Figure 4A ) and SK-1 translocation from the cytosol to the cell membrane ( Figure 4B ), which is important for its activation, in siFHL EOCs compared with siLuci EOCs. This was associated with a significant increase in the intracellular levels of S1P (0.16±0.02 versus 0.10±0.01 µmol/L; Figure 4C ) as well as phosphorylation of Akt ( Figure 4D ), which is a downstream effector of S1P. We also investigated the effect of exogenous S1P on EOC function; apoptosis was reduced and SDF-1-induced migration increased in S1P-stimulated EOCs compared with vehicle-stimulated EOCs ( Figure 4E and 4F), similar to what we found in siFHL EOCs (Figures 2  and 3 ). To further test the causal relationship between siFHL, SK-1 upregulation, and EOC function, we used the specific pharmacological SK-1 inhibitor CAY10621. We found that the reduced apoptosis, the increased SDF-1-induced migration, and the increased cortactin expression in EOCs with FHL2 knockdown were completely abolished by CAY10621 ( Figure 5A -5C). Because S1P could be secreted in the extracellular space and bind to its specific receptors by autocrine effects, we investigated if the antiapoptotic and promigratory effects of FHL2 silencing are mediated through activation of S1P receptor-1 and -3 (S1PR-1/-3). The S1PR-1/-3 antagonist VPC23019 increased basal apoptosis and completely abolished the reduction in apoptosis observed with siFHL ( Figure 5A ). Moreover, VPC23019 decreased basal SDF-1-induced migration and partly inhibited the promigratory effect of FHL2 silencing ( Figure 5B ). Taken together, these data suggest that the antiapoptotic effect observed with . Four-and-a-half LIM domain protein-2 (FHL2) knockdown regulates human early outgrowth cell (EOC) function through activation of the sphingosine kinase-1 (SK-1)/sphingosine-1-phosphate (S1P) pathway. Human mononuclear cells were isolated and cultured on fibronectin for 7 days. A to D, Cells were transfected on day 6 with FHL2 siRNA (siFHL) or luciferase siRNA (siLuci) for 24 hours. Phosphorylated (p-) and total forms of SK-1 (A and B) and Akt (D) were assessed in cytoplasmic (Cyto) or membrane (Mem) fractions or in wholecell lysates. Means±SEM of n=4 to 5; *P<0.05 and **P<0.01 vs siLuci. C, S1P levels were assessed by ELISA in whole-cell lysates. Bar graph represents means±SEM of n=4; *P<0.05 vs siLuci. E and F, Endothelial progenitor cells were stimulated with S1P or vehicle (Veh) for 24 hours. S1P reduced EOC apoptosis (E) and increased EOC migration (F). Results are means±SEM of n=3; *P<0.05 and **P<0.01 vs Veh. knockdown increases human early outgrowth cell migration through upregulation of αv/β3, αv/β5, and β2 integrins. Human mononuclear cells were isolated and cultured on fibronectin for 7 days. Cells were transfected on day 5 with FHL2 siRNA (siFHL) or luciferase siRNA (siLuci) for 24 hours. A, Boyden chamber assays were used to investigate migration of Dil-acetylated low density lipoprotein/lectin double-positive endothelial progenitor cells (EPCs). Data are means±SEM of n=6; **P<0.001 vs siLuci. B, Fluorescence-activated cell sorting analysis was performed to detect αv/β3, αv/β5, and active forms of β1 and β2 integrins in cultured EPCs. Bar graphs represent means±SEM of n=4 to 6; *P<0.05 vs siLuci. C, EPCs were incubated with specific blocking antibodies against αv/β3, αv/β5, active forms of β1 and β2, or IgG before Boyden chamber migration. Data are means±SEM of n=4; **P<0.001 vs siLuci plus vehicle (Veh); †P<0.05 and † †P<0.01 vs siFHL plus Veh; ##P<0.01 vs siLuci plus IgG. D, Cortactin expression was assessed by immunocytochemistry. Bar graphs are means±SEM of n=6; *P<0.05 vs siLuci; scale bar, 50 µm.
siFHL2 is mediated through activation of SK-1, increased production of S1P, and activation of S1PR-1/-3. The promigratory effect of FHL2 silencing is also mediated through activation of SK-1 and increased S1P production, but is only partly mediated by S1PR-1/-3.
FHL2 −/− EOCs Show Increased Cell Numbers, Reduced Apoptosis, and Enhanced Migration
The human cell data were verified by using spleen-derived cultured EOCs from FHL2 −/− and WT mice. Interestingly, FHL2 −/− mice contained more spleen-derived EOCs compared with their WT counterpart (Online Figure V) . The number, apoptosis, and migratory capacity of these cells were assessed. Confirming the human EOC results, the number of Dil-acLDL/lectin double-positive mouse EOCs was significantly increased (Figure 6A 
FHL2 −/− EOCs Have Enhanced Paracrine Effects on ECs Through Increased S1P Secretion and Activation of S1PRs
Because we demonstrated that FHL2 knockdown activates SK-1 and increases S1P production in EOCs, we tested the hypothesis that increased S1P production and release into the extracellular space would lead to subsequent regulation of EC function. First, we verified the effect of exogenous S1P on ECs; S1P significantly increased EC migratory capacity and decreased EC cleaved caspase-III expression ( Figure 7A and 7B). Second, to determine whether absence of FHL2 regulates secretion of S1P by EOCs, we measured S1P levels in the conditioned medium (cm) of EOCs from WT (cmWT) and FHL2 −/− mice (cmFHL). S1P was significantly enhanced in cmFHL compared with cmWT (0.12±0.02 versus 0.08±0.01 µmol/L, respectively; Figure 7C ). Third, we exposed murine ECs to cmFHL or cmWT. We observed a significant increase in migration and decrease in cleaved caspase-III expression in ECs exposed to cmFHL versus cmWT ( Figure 7D and 7E) . Finally, ECs were pretreated with S1PR-1/-3 antagonist VPC23019 or vehicle before being exposed to cmWT or cmFHL. Increased migration and decreased cleaved caspase-III expression after stimulation with cmFHL were completely abolished by the S1PR-1/-3 antagonist (Figure 7D and 7E ). These results demonstrate that absence of FHL2 in EOCs regulates production and secretion of S1P by these cells, which in turn regulates EC function through activation of S1PRs.
FHL2 −/− EOCs Have an Increased Reendothelialization Capacity
To investigate the functional significance of FHL2 deletion in EOCs in vivo, we assessed reendothelialization capacity of these cells after focal carotid endothelial injury in mice. Carotid artery electric injury was induced in splenectomized WT mice, and spleen-derived cultured EOCs from WT or FHL2 −/− donor mice, or saline, were injected intravenously. Subsequently, carotid artery reendothelialization was assessed after staining with Evans blue dye. Figure 8A demonstrates that injection of EOCs from WT mice enhanced reendothelialization by 28±4% compared with saline injection. Importantly, injection of EOCs from FHL2 −/− mice significantly enhanced reendothelialization by an additional 30±2% as compared with WT EOC injection. Moreover, although the total number of EOCs attached to the arterial wall was low, we observed a 2-fold increase in vascular wall attachment of labeled FHL2 −/− EOCs compared with WT EOCs (cell number/injured area ratio, 16±1.9 versus 8.6±1.7; Figure 8C ). These findings clearly indicate the functional relevance of FHL2 knockout for enhanced EOC function in vivo.
Discussion
The present study demonstrates that FHL2 is a negative regulator of EOC number and function. We showed, for the first time to our knowledge, that FHL2 is expressed in EOCs. Inhibition of FHL2 increases EOC survival and migratory capacity by activating the SK-1/S1P pathway and upregulating αv/β3 and αv/β5 integrins. Moreover, inhibition of FHL2 regulates paracrine functions of EOCs, which leads to enhanced EC survival and migration through activation of S1PRs on ECs. Ultimately, inhibition of FHL2 results in improvement of endothelial regeneration by EOCs (Online Figure VI) . FHL2 is expressed by vascular smooth muscle cells and ECs, 21, 22 suggesting a potential role of FHL2 in the vasculature. 9 However, the expression and function of FHL2 in EOCs was previously unknown. We demonstrated in vitro that inhibition of FHL2 in both human and murine EOCs increased their numbers. We observed a low rate of proliferation in EOCs in this and previous studies, 28 and there was no effect of FHL2 inhibition on adhesion of EOCs to ECs or several matrix proteins. However, the apoptosis rate in human and murine EOCs with low FHL2 was significantly reduced. These data suggest that FHL2 inhibition supports prosurvival signaling in EOCs. Contradictory data are described in the literature regarding the effect of FHL2 on apoptosis in cell lines. Ectopic expression of FHL2 triggered apoptosis in COS1 cells, NIH 3T3 cells, and rhabdomyosarcoma cells. 30 However, FHL2 failed to show any proapoptotic role in HeLa and human embryonic kidney 293 cells. 31 Similarly, FHL-2 has divergent trophic effects, supporting proliferation in cancer cells 32 but abating cardiac hypertrophic growth. 33 These studies suggest that FHL2 may exert opposing biological functions in different cell types, possibly related to its interaction with diverse protein partners. −/− mice. Cells were cultured for 7 days; conditioned medium (cm) was collected at day 6 for S1P quantification. Means±SEM of n=4; *P<0.05 vs cmWT. D and E, Mouse ECs were pretreated with Veh or VPC23019 (20 nmol/L), an antagonist of S1P receptor-1 and -3 (S1PR-1/-3), and then exposed to cm for 15 hours. D, Migration was assessed by scratch assay. Bar graphs are means±SEM of n=4 to 6; *P<0.05 vs cmWT plus Veh; †P<0.05 vs cmFHL plus Veh; scale bar, 50 µm. E, Apoptosis was determined by cleaved caspase-III expression. Means±SEM of n=4 to 6; **P<0.01 vs cmWT plus Veh; †P<0.05 vs cmFHL plus Veh; scale bar, 25 µm.
An important functional property of EOCs, essential for EOC-mediated reendothelialization, is their ability to migrate. We observed a significant increase in the migratory capacity of EOCs after inhibition or in the absence of FHL2. Our results are in agreement with the literature; it was reported that overexpression of FHL2 inhibits vascular endothelial growth factor-induced EC migration. 23 Moreover, another recent study showed that FHL2 is an important regulator of chemotactic dendritic cell migration. 34 Integrins play a key role in cell motility, and we found a significant increase in αv/β5 and αv/β3 subunit expression in human EOCs after FHL2 knockdown. In contrast, active β1 and β2 subunits were unchanged. Interestingly, specific blocking antibodies against αv/β5, αv/β3, and β2 integrins abolished the increase in migration associated with siFHL2. αv/β3 and αv/β5 integrins were shown to be involved in restenosis after angioplasty and constrictive vascular remodeling after injury through stimulation of smooth muscle cell migration. 35 They have been shown to stimulate EC migration as well.
36,37 β 2 integrins are well known to mediate transendothelial migration of human peripheral blood-derived EOCs. Our data indicate that FHL2 inhibition enhances SDF-1-induced EOC migration through αv/β3, αv/β5, and β2 integrins. In contrast, β 1 integrin does not seem to be involved in this process.
Previous studies reported that FHL2 binds to SK-1 26 and that this interaction inhibits SK-1 activity. 23 Activation of SK-1 involves its phosphorylation and translocation to the cell membrane where its substrate, sphingosine, is located.
24,25 SK-1 produces S1P, a bioactive sphingolipid that is known to act extracellularly via binding to 5 receptors of the lysophospholipid receptor family (S1PR-1-5).
38 S1P has intracellular effects as well, acting as a signaling molecule and promoting cell survival, proliferation, and differentiation. S1P acts as a potent angiogenic mediator in ECs and cultured EOCs and stimulates the neovascularization capacity of EOCs and bone marrow cells. 39, 40 Likewise, SK-1 is involved in NO-mediated EC migration and tube formation. 41 Recently, it was reported that FHL2 regulates phosphatidylinositol-3-kinase/Akt via direct suppression of the SK-1/ S1P pathway in ECs. 23 Moreover, regulation of dendritic cell migration by FHL2 involves activation of S1PR-1. 34 Therefore, we hypothesized that FHL2 inhibition in EOCs could activate the SK-1/S1P system, leading to the activation of prosurvival and promigratory pathways. We observed less apoptosis and enhanced SDF-1-induced migration in EOCs stimulated with exogenous S1P. We also showed that FHL2 knockdown increased SK-1 phosphorylation and translocation to the membrane and increased intracellular S1P levels and Akt phosphorylation. It has been reported that SK-1 enhances resistance to apoptosis through activation of the phosphatidylinositol-3-kinase/Akt/NF-κB pathway in different cell types. 42, 43 Furthermore, S1P has antiapoptotic effects in human embryonic stem cells through extracellular signalregulated kinase-1/2 and phosphatidylinositol-3-kinase/Akt signaling pathways. 43, 44 Importantly, we observed that SK-1 inhibition completely prevented the reduction of apoptosis and the increase of migration associated with siFHL2, suggesting that inhibition of FHL2 regulates survival and migration of EOCs through activation of SK-1. Our results are in agreement with a report showing that inhibition of FHL2 in cardiomyocytes prevents myocardial apoptosis through activation of SK-1. 26 To verify if S1P produced by EOCs acts intracellularly or is secreted and binds to its receptors present on the surface of EOCs by an autocrine effect, we used an antagonist of S1PR-1/-3. We found that the antagonist increased basal apoptosis and reduced basal migration. Moreover, the decrease in apoptosis induced by FHL2 siRNA was abolished by the antagonist. However, the antagonist only partially inhibited the increase in migration induced by FHL2 siRNA. These data suggest that S1P acts through S1PR-1/-3 to regulate EOC survival, and that the effect of FHL2 siRNA on EOC migration may involve intracellular S1P signaling or other S1PRs. The role of S1P in SDF-1-induced migration and bone marrow homing of human CD34 + progenitor cells has been reported.
45 S1P-induced cell migration is dependent on the translocation of the cortactin-actin-related protein-2/3 complex (Arp2/3) to the lamellipodia region. 46 Cortactin is an actin-binding protein. It is a substrate of Src kinase and is activated by tyrosine phosphorylation, leading to membrane ruffling, cortical actin assembly, lamellipodia formation, and cell mobility, 47 suggesting a critical role of cortactin in cellular migration. Because LIM domain proteins are involved in cytoskeleton organization 48 and our results show that FHL2 regulates EOC migration, we investigated the effect of FHL2 inhibition on the expression of cortactin in EOCs. We found a significant increase in cortactin with FHL2 siRNA, which was abolished with the SK-1 inhibitor. Similarly, S1P was shown to induce membrane ruffling and cortical actin assembly in human umbilical vein ECs, which ultimately resulted in endothelial chemotactic responses. 49 Taken together, our results show that inhibition of FHL2 activates the SK-1/S1P/Akt pathway, which in turn could upregulate αv/β3 and αv/β5 integrins as well as cortactin, leading to actin organization and increased EOC migration. However, the exact mechanisms involved in the activation of integrins or cortactin by S1P need further investigation.
EOCs have been shown to participate in endothelial repair either by differentiating into mature ECs or by producing soluble factors that act in a paracrine manner to mobilize tissueresiding progenitor cells or to regulate EC functionality. 29, 50 Considering this, we tested the hypothesis that FHL2 inhibition in EOCs regulates the secretion of paracrine factors that could in turn influence EC function. Having shown that FHL2 inhibition activates the SK-1/S1P pathway in EOCs, we first confirmed that this leads to S1P secretion into the extracellular space. S1P levels were enhanced in the conditioned media of FHL2 −/− EOCs (cmFHL) compared with WT EOCs (cmWT). Because S1PRs are also present on the surface of ECs, S1P secreted by EOCs could affect ECs in a paracrine manner. We found that cmFHL, but not cmWT, reduced EC apoptosis and increased EC migration. Moreover, pretreatment of ECs with a S1PR-1/-3 antagonist not only completely abolished these effects induced by cmFHL, but also further increased the apoptosis rate in ECs. Several studies reported the strong EC cytoprotective properties of factors released by EOCs, such as vascular endothelial growth factor, SDF-1, insulin-like growth factor-1, and thymidine phosphorylase. 29, [50] [51] [52] Our data add S1P to this list of factors and reveal a critical role for FHL2 in regulating its release. Our results also support the notion that signaling pathways regulated by S1PR-1/-3 are required for EC chemotaxis, adherence junction assembly, EC morphogenesis, and angiogenesis in vitro and in vivo. 50, 53, 54 Hence, we showed, for the first time to our knowledge, that inhibition or absence of FHL2 in EOCs improves EOC paracrine functions through activation of the SK-1/S1P pathway, which in turn activates S1PR-1/-3 on ECs, leading to an increase of EC survival and migratory capacity.
Circulating EOCs contribute to endothelial regeneration by homing to and regulating ECs via paracrine signals. 4, 28 To assess the functional in vivo relevance of FHL2 inhibition in EOCs, we investigated carotid artery reendothelialization after injury. Importantly, we observed that reendothelialization was enhanced after intravenous injection of EOCs from FHL2 −/− mice compared with EOCs from WT mice. In conjunction, FHL2
−/− EOC incorporation at the site of injury was 2-fold higher compared with WT EOC. These results could be explained by an increased survival of FHL2
−/− cells, in line with our in vitro data. The recruited EOCs were scattered among the new cells lining the site of injury, which supports the notion that the EOCs act mostly by paracrine functions. Our findings, therefore, underline the pathophysiological relevance of FHL2 expression in circulating cells.
In summary, our data show, for the first time to our knowledge, that FHL2 is a strong negative regulator of EOC number, survival, and migratory capacity through regulation of the SK-1/S1P pathway. On the one hand, FHL2 knockdown in EOCs improves EOC functions by activating SK-1 and Akt, leading to a reduction of apoptosis, upregulation of integrins, and enhancement of migration. On the other hand, FHL2 knockdown improves EC function by paracrine effects, through regulation of S1P secretion by EOCs and S1PR-1 or S1PR-3 activation on ECs, leading to a reduction in EC apoptosis and increased EC migration. This study, with a considerable clinical relevance, provides mechanistic insight into the regulation of EOC survival and function and identifies a novel factor that may constitute a target with therapeutic potential. 
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FHL2 is highly expressed in vascular cells. It can regulate cell function and structure by interacting with multiple proteins at specific sites in the cell. However, the role of FHL2 in EOCs is not known. Here, we report that knockdown of FHL2 in human EOCs significantly increases their number, viability, and migration through activation of SK-1, the enzyme that produces S1P, and upregulation of integrins. We also found that knockdown of FHL2 regulates the secretion of S1P by EOCs that improves endothelial cell function via activation of its receptor, S1PR-1/-3, expressed on the surface of endothelial cells. Importantly, absence of FHL2 in EOCs increases their capacity to repair the endothelium. These findings support the notion that FHL2 is a potential therapeutic target to improve EOC function to combat diminished endothelial regeneration, which is considered to play an essential role in vascular pathogenesis.
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